The company can't get good enough adjudication in a US trial to demonstrate accuracy for individual diseases. So clearly they have pulled back to a broader target in order to get greater confidence.
This is a serious erosion of the company's aspirations. Forget any near or medium term prospects of ResappDx becoming a diagnostic tool for specific conditions in the USA.
The new certification, when it eventually is granted, will allow ResappDx to be used to indicate that a LRTI exists. This is something any medical practitioner can do in 90 seconds with a stethoscope. The only advantages of ResappDx under those conditions are:
- Patient doesn't have to take off their shirt.
- Symptoms can be measured at a distance, without direct contact.
- Forums
- ASX - By Stock
- RAP
- Ann: Pre-Submission package lodged with the US FDA
Ann: Pre-Submission package lodged with the US FDA, page-19
-
-
- There are more pages in this discussion • 181 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)